Encorafenib (LuciEncor) and Binimetinib (LuciBinim) are oral medicines that are taken together as a combination treatment. Doctors may recommend this therapy for adults with advanced melanoma that has a BRAF mutation, and for some patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC).
How Does This Treatment Work?
Cancer cells often grow and spread because of changes in certain signaling pathways inside the body. One of the most important is called the MAPK pathway, which acts like a “switch” that tells cells to keep dividing.
- Encorafenib (LuciEncor) blocks the abnormal activity of the BRAF protein, stopping the signal at its source.
- Binimetinib (LuciBinim) works further down the pathway, blocking MEK1 and MEK2, which carry the signal forward.
By working together, these two medicines provide a “double block,” slowing down cancer cell growth and helping to control the disease more effectively than one medicine alone.
Why Is This Important?
For patients with BRAF-mutant melanoma or lung cancer, this targeted therapy offers:
- Personalized treatment based on the genetic profile of the tumor
- Better disease control, helping slow down cancer progression
- Improved quality of life, giving patients more time and comfort with their loved ones
A Helpful Reminder
While many patients benefit from this therapy, everyone responds differently. Side effects and results can vary. Always follow your doctor’s instructions and let them know about any changes in how you feel during treatment.
